Non Animal Testing Database

A prognostic Alzheimer’s disease blood test in the symptom-free stage

December 2020
Ruhr University Bochum, Bochum, Germany
The authors evaluated amyloid-beta misfolding as a prognostic tool for future clinical progression to mild cognitive impairment or dementia due to Alzheimer’s disease (AD) in 203 individuals with subjective cognitive decline over the course of 6 years. The results suggest that a panel of structure- and concentration-based plasma amyloid biomarkers may predict conversion to clinical mild cognitive impairment and dementia due to AD in cognitively unimpaired subjects. These plasma biomarkers provide a noninvasive and cost-effective alternative for screening early AD pathological changes.
Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline
Klaus Gerwert
Added on: 01-29-2021
Back to Top
English German

Warning: Internet Explorer

The IE from MS no longer understands current scripting languages, the latest main version (version 11) is from 2013 and has not been further developed since 2015.

Our recommendation: Use only the latest versions of modern browsers, for example Google Chrome, Mozilla Firefox or Microsofrt Edge, because only this guarantees you sufficient protection against infections and the correct display of websites!